Brincidofovir

Brincidofovir

Clinical data
Synonyms	CMX001; Cidofovir-HDP; hexadecyloxypropyl-cidofovir
Legal status
Legal status	US: Investigational
Identifiers
CAS Number	444805-28-1
PubChem CID	483477
ChemSpider	424003
ChEMBL	CHEMBL203321
Chemical and physical data
Formula	C27H52N3O7P
Molar mass	561.70 g/mol
3D model (JSmol)	Interactive image
SMILES CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](CN1C=CC(=NC1=O)N)CO)O
InChI InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1 Key:WXJFKKQWPMNTIM-VWLOTQADSA-N

Brincidofovir (CMX001) is an experimental antiviral drug being developed by Chimerix of Durham, NC, for the treatment of cytomegalovirus, adenovirus, smallpox, and ebolavirus infections. Brincidofovir is a prodrug of cidofovir. Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as oral bioavailability.

In animal trials the drug has shown activity against cytomegalovirus, adenoviruses, BK virus, smallpox, and herpes simplex viruses. Preliminary in vitro tests have also shown it to have potential for the treatment of Ebola virus disease, which is somewhat paradoxical, as Ebola is not a DNA virus.

Brincidofovir is currently in Phase III clinical trials for use in humans against cytomegalovirus and adenovirus, after testing for safety in over 1000 human subjects, and has received FDA Fast Track Designation for treatment of cytomegalovirus, adenovirus, and smallpox. Chimerix announced in December 2015 that the Phase III trials for use of the drug in preventing cytomegalovirus infection in stem cell transplant patients had failed, and in February 2016 shut down two other late-stage trials for use of the drug in preventing infection after kidney transplants. The company is planning on returning trials of the drug for use in stem cell transplant patients to Phase II, while continuing to advance a late-stage trial for use against adenovirus infections in patients suffering from weakened immune systems.